Our platform has delivered multiple validated targets in inflammation, fibrosis, and other disease areas. We have a growing pipeline of earlier stage clinical assets based on novel targets discovered by us.
GLPG3667 is a proprietary compound with an undisclosed mechanism of action in development for inflammatory and autoimmune indications. Based on an initial clinical study in healthy volunteers, GLPG3667 met the criteria to be further studied in patients. Galapagos has initiated a Phase 1b trial in psoriasis with GLPG3667, with first patient dosed in November 2020.
GLPG2737 is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) inhibitor which was shown to be well tolerated by patients in previous clinical trials. It is hypothesized that inhibition of the CFTR channel might reduce cyst growth and enlargement for patients with autosomal dominant polycystic kidney disease (ADPKD). In December 2020, the first dosing with GLPG2737 in the Phase 2 MANGROVE trial in patients with ADPKD was announced.